Application | Comment | Organism |
---|---|---|
medicine | anti-cancer therapy | Homo sapiens |
Cloned (Comment) | Organism |
---|---|
expressed in Escherichia coli | Homo sapiens |
Crystallization (Comment) | Organism |
---|---|
- |
Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
N161H | results in the total loss of the enzymatic activity towards activation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide, whereas the rates of reduction towards menadione are not altered | Homo sapiens |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
0.061 | - |
5-(aziridin-1-yl)-2,4-dinitrobenzamide | at 25°C in pH 8.5 buffer (50 mM Tris, 140 mM NaCl, and 0.1% Tween 20) with 0.1 mM menadione as co-substrate | Homo sapiens |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
Zn2+ | - |
Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Purification (Comment) | Organism |
---|---|
DEAE Sepharose, Superdex 75 column chromatography and Mono-Q column chromatography | Homo sapiens |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
5-(aziridin-1-yl)-2,4-dinitrobenzamide + menadiol | - |
Homo sapiens | ? + reduced menadiol | - |
? |
Synonyms | Comment | Organism |
---|---|---|
NQO2 | - |
Homo sapiens |
NRH:quinone oxireductase 2 | - |
Homo sapiens |
QR2 | - |
Homo sapiens |
quinone reductase 2 | - |
Homo sapiens |
Turnover Number Minimum [1/s] | Turnover Number Maximum [1/s] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
6 | - |
5-(aziridin-1-yl)-2,4-dinitrobenzamide | at 25°C in pH 8.5 buffer (50 mM Tris, 140 mM NaCl, and 0.1% Tween 20) with 0.1 mM menadione as co-substrate | Homo sapiens |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
FAD | - |
Homo sapiens |